Statin use after intracerebral hemorrhage: a 10-year nationwide cohort study

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Statin therapy benefits ischemic stroke patients but its use in intracerebral hemorrhage (ICH) survivors raises concerns.
• ICH survivors often have cardiovascular risk factors necessitating cholesterol-lowering medication.
• Assessing statin therapy characteristics in post-ICH patients is crucial.

Purpose of the Study:

• To evaluate the impact of statin intensity and type (hydrophilic vs. lipophilic) on outcomes in patients with a history of intracerebral hemorrhage.
• To determine if statin therapy influences the risk of recurrent ICH, mortality, or other cardiovascular events in this population.

Main Methods:

• A 10-year cohort study using Taiwan's National Health Insurance Research Database.
• Inclusion of 726 patients newly diagnosed with ICH.
• Categorization into high, moderate, and low statin intensity groups, and hydrophilic vs. lipophilic statin groups.
• Composite outcomes included all-cause mortality, recurrent ICH, ischemic stroke, transient ischemic attack, and acute coronary events.

Main Results:

• Hydrophilic statin use was associated with a significantly lower risk of recurrent ICH compared to lipophilic statin use (aHR = 0.69, 95% CI = 0.48-0.99).
• No significant differences were observed in the risk of all-cause mortality or recurrent ICH between low-intensity and high-intensity statin groups.
• No significant differences were found in other composite endpoints between hydrophilic and lipophilic statin groups.

Conclusions:

• Hydrophilic statin therapy may be associated with a reduced risk of recurrent ICH in patients with a history of ICH.
• Statin intensity does not appear to significantly affect the risk of recurrent ICH or other composite outcomes in this population.
• Further research is warranted to elucidate the biological mechanisms behind these findings.